NCT04493671View on ClinicalTrials.gov

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

137

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

June 16, 2022

Study Completion Date

November 15, 2022

Conditions

Pulmonary DiseaseTuberculosis, PulmonaryTuberculosisMulti Drug Resistant TuberculosisDrug Sensitive TuberculosisDrug-resistant TuberculosisMycobacterium Tuberculosis Infection

Interventions

DRUG

TBAJ-876 suspension

TBAJ-876 oral suspension, orally administered

DRUG

Placebo suspension

Placebo for TBAJ-876 oral Suspension; orally administered

DRUG

TBAJ-876 100 mg tablet

TBAJ-876 100 mg tablets, orally administered

DRUG

TBAJ-876 25 mg tablet

TBAJ-876 25 mg tablets, orally administered

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors

lead

Global Alliance for TB Drug Development

OTHER

NCT04493671 - Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults | Biotech Hunter | Biotech Hunter